References
1. Hastan D, Fokkens WJ, Bachert C, Newson RB, Bislimovska J,
Bockelbrink A, et al. Chronic rhinosinusitis in Europe–an
underestimated disease. A GA(2)LEN study. Allergy.66(9):1216-23.
2. Jarvis D, Newson R, Lotvall J, Hastan D, Tomassen P, Keil T, et al.
Asthma in adults and its association with chronic rhinosinusitis: the
GA2LEN survey in Europe. Allergy.67(1):91-8.
3. Mucci T, Govindaraj S, Tversky J. Allergic rhinitis. Mt Sinai J Med.
2011;78(5):634-44.
4. Caulley L, Thavorn K, Rudmik L, Cameron C, Kilty SJ. Direct costs of
adult chronic rhinosinusitis by using 4 methods of estimation: Results
of the US Medical Expenditure Panel Survey. J Allergy Clin
Immunol.136(6):1517-22.
5. Rudmik L, Soler ZM. Medical Therapies for Adult Chronic Sinusitis: A
Systematic Review. JAMA.314(9):926-39.
6. Tversky JR, Bieneman AP, Chichester KL, Hamilton RG, Schroeder JT.
Subcutaneous allergen immunotherapy restores human dendritic cell innate
immune function. Clinical and experimental allergy : journal of the
British Society for Allergy and Clinical Immunology. 2010;40(1):94-102.
7. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et
al. Omalizumab is effective in allergic and nonallergic patients with
nasal polyps and asthma. J Allergy Clin Immunol.131(1):110-6 e1.
8. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A
randomized, double-blind, placebo-controlled trial of anti-IgE for
chronic rhinosinusitis. Rhinology.48(3):318-24.
9. Yalcin AD, Ucar S, Gumuslu S, Strauss LG. Effects of omalizumab on
eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1beta and sCD200 in
cases of Samter’s syndrome: 36 months follow-up. Immunopharmacol
Immunotoxicol.35(4):524-7.
10. Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al.
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase
3 trials. The Journal of allergy and clinical immunology. 2020.
11. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P,
et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in
Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized
Clinical Trial. JAMA. 2016;315(5):469-79.
12. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et
al. Dupilumab in persistent asthma with elevated eosinophil levels. N
Engl J Med. 2013;368(26):2455-66.
13. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et
al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020.
Rhinology. 2020;58(Suppl S29):1-464.
14. Nakayama T, Yoshikawa M, Asaka D, Okushi T, Matsuwaki Y, Otori N, et
al. Mucosal eosinophilia and recurrence of nasal polyps - new
classification of chronic rhinosinusitis. Rhinology. 2011;49(4):392-6.
15. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke
F, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option
for severe nasal polyposis. The Journal of allergy and clinical
immunology. 2011;128(5):989-95 e1-8.
16. Baer AN, Okuhama A, Eisele DW, Tversky JR, Gniadek TJ. Eosinophilic
sialodochitis: redefinition of ’allergic parotitis’ and ’sialodochitis
fibrinosa’. Oral Dis. 2016.
17. Liu Z, Kim J, Sypek JP, Wang IM, Horton H, Oppenheim FG, et al. Gene
expression profiles in human nasal polyp tissues studied by means of DNA
microarray. The Journal of allergy and clinical immunology.
2004;114(4):783-90.
18. Ghazi A, Trikha A, Calhoun WJ. Benralizumab–a humanized mAb to
IL-5Ralpha with enhanced antibody-dependent cell-mediated
cytotoxicity–a novel approach for the treatment of asthma. Expert
Opin Biol Ther. 2012;12(1):113-8.
19. FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I,
Metcalfe P, et al. Predictors of enhanced response with benralizumab for
patients with severe asthma: pooled analysis of the SIROCCO and CALIMA
studies. Lancet Respir Med. 2018;6(1):51-64.
20. Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head
Neck Surg. 1997;117(3 Pt 2):S35-40.
21. Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology.
1993;31(4):183-4.
22. Shtessel M, Tversky J. Reliability of Allergen Skin Testing Is
Highly Dependent on the Precise Control Reagents Selected. The Journal
of allergy and clinical immunology. 2017;139(2):AB157.
23. Tversky JR, Chelladurai Y, McGready J, Hamilton RG. Performance and
Pain Tolerability of Current Diagnostic Allergy Skin Prick Test Devices.
J Allergy Clin Immunol Pract. 2015;3(6):888-93.
24. Tversky J, MacGlashan D. Short-wave infrared camera as a novel
solution to allergy skin testing. Allergy. 2020;75(4):965-8.
25. Naclerio R, Baroody F, Bachert C, Bleier B, Borish L, Brittain E, et
al. Clinical Research Needs for the Management of Chronic Rhinosinusitis
with Nasal Polyps in the New Era of Biologics: A National Institute of
Allergy and Infectious Diseases Workshop. J Allergy Clin Immunol Pract.
2020;8(5):1532-49 e1.
26. Bachert C, Gevaert P, Hellings P. Biotherapeutics in Chronic
Rhinosinusitis with and without Nasal Polyps. J Allergy Clin Immunol
Pract. 2017;5(6):1512-6.
27. Han J, Bachert C, Derosiers M, Laidlaw T. Efficacy and Safety of
Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps. The
Journal of allergy and clinical immunology. 2019.
28. Bachert C, Marple B, Hosemann W, Cavaliere C, Wen W, Zhang N.
Endotypes of Chronic Rhinosinusitis with Nasal Polyps: Pathology and
Possible Therapeutic Implications. J Allergy Clin Immunol Pract.
2020;8(5):1514-9.
29. Stevens WW, Peters AT, Tan BK, Klingler AI, Poposki JA, Hulse KE, et
al. Associations Between Inflammatory Endotypes and Clinical
Presentations in Chronic Rhinosinusitis. J Allergy Clin Immunol Pract.
2019;7(8):2812-20 e3.
30. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H,
et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster
analysis of biomarkers. The Journal of allergy and clinical immunology.
2016;137(5):1449-56 e4.
31. Paris G, Pozharskaya T, Asempa T, Lane AP. Damage-associated
molecular patterns stimulate interleukin-33 expression in nasal polyp
epithelial cells. Int Forum Allergy Rhinol. 2014;4(1):15-21.
32. Tversky JR, Le TV, Bieneman AP, Chichester KL, Hamilton RG,
Schroeder JT. Human blood dendritic cells from allergic subjects have
impaired capacity to produce interferon-alpha via Toll-like receptor 9.
Clinical and experimental allergy : journal of the British Society for
Allergy and Clinical Immunology. 2008;38(5):781-8.
33. Borish L, Hamilos DL. Endotype-Phenotype Correlation in Chronic
Rhinosinusitis: Is It Time to Think Beyond Polyposis? J Allergy Clin
Immunol Pract. 2019;7(8):2821-2.
34. Laidlaw TM, Prussin C, Panettieri RA, Lee S, Ferguson BJ, Adappa ND,
et al. Dexpramipexole depletes blood and tissue eosinophils in nasal
polyps with no change in polyp size. Laryngoscope. 2019;129(2):E61-E6.